Small cell lung cancer (SCLC) is notoriously difficult to treat because it excels at evading the immune system. Yet that tactic should leave it vulnerable to natural killer (NK) cells, which are designed to destroy exactly the types of cells SCLC produces. So why are NK cells largely absent from these tumors? Researchers at the University of Michigan set out to find the answer. Read on to learn what they discovered.
